Molecular Partners (MOLN) Q4 2025 earnings review
Zero Revenue, But a Cleaner Radiopharma Story and Leaner Cost Base
Molecular Partners closed FY25 with a complete reversing of revenue to zero following the end of its Novartis collaboration. However, the core operating narrative is improving. Aggressive mid-year restructuring reduced headcount by 15%, successfully decelerating operating expenses by CHF 8.1M to CHF 58.1M. While the bottom-line net loss widened to CHF 61.6M due to unfavorable FX and financial results, the operational burn is under control. The company has fully pivoted to its Radio-DARPin Therapy (RDT) pipeline, with lead candidate MP0712 showing specific tumor uptake and entering Phase 1/2a. With cash at CHF 93.1M, the company's survival into its guided 2028 runway is highly dependent on hitting its strict CHF 45-55M 2026 OpEx target.
🐂 Bull Case
The 2025 restructuring successfully cut operating expenses from CHF 66.2M to CHF 58.1M, with 2026 guidance pointing to an even leaner CHF 45-55M. This disciplined cash management secures the runway to 2028.
Lead candidate MP0712 has entered US Phase 1/2a trials, with preliminary 203Pb imaging already proving specific tumor uptake and washout from healthy organs—validating the core DARPin hypothesis.
🐻 Bear Case
Revenue went from CHF 5.0M in FY24 to absolute zero in FY25. The company is now entirely dependent on its cash reserves and future, yet-to-be-signed partnerships.
Former lead platforms (Immune Engagers) are increasingly being outsourced to Investigator-Initiated Trials (IITs), suggesting a lack of internal confidence or capital to push them forward aggressively.
⚖️ Verdict: ⚪
Neutral. The pipeline pivot to radiopharmaceuticals is timely and early imaging data is highly encouraging. However, with zero incoming revenue and a net loss exceeding CHF 61M, the execution risk on their clinical milestones over the next 18 months is immense.
Key Themes
MP0712 Clinical Momentum Accelerating
The lead Radio-DARPin, MP0712 (targeting DLL3), has officially opened its Phase 1/2a study in the US. Crucially, early human imaging data using the 203Pb diagnostic isotope showed specific tumor uptake and favorable washout from healthy organs (kidneys/red marrow). Safety data is expected in H1 2026, with initial activity data in H2 2026. This transforms MOLN from a platform-concept company into a clinical-stage radiopharma player.
Isotope-Agnostic Expansion via Eckert & Ziegler
A new development agreement with Eckert & Ziegler allows Molecular Partners to pair its DARPins with Actinium-225 (225Ac), expanding beyond its existing 212Pb partnership with Orano Med. This 'alpha-agnostic' capability is a major strategic driver, mitigating supply chain risks associated with a single isotope and allowing the company to match the specific half-life of an isotope to the biological behavior of different tumors.
Restructuring Successfully Decelerates Burn
The strategic review in mid-2025 achieved its goal. Full-Time Equivalents (FTEs) dropped from 158.5 to 134.0, which helped pull operating expenses down by CHF 8.1M YoY. R&D expenses specifically fell from CHF 48.6M to CHF 40.2M. The company now expects to operate on a highly controlled CHF 45-55M budget in 2026.
Revenue Reversing to Absolute Zero
Following the conclusion of the Novartis collaboration in Q3 2024, Molecular Partners recorded CHF 0 in revenue for FY25 (down from CHF 5.0M in FY24). With the Switch-DARPin candidate MP0621 still merely 'being evaluated for partnering,' the company has no visible near-term commercial or milestone revenue streams, placing 100% of the funding burden on the balance sheet.
Net Loss Widening Due to Financial Headwinds
Despite a CHF 3.1M improvement in operating results, the bottom-line net result worsened from a CHF 54.0M loss to a CHF 61.6M loss. This was driven by a massive reversal in the net financial result, which flipped from a CHF +7.2M gain in 2024 to a CHF -3.5M loss in 2025, primarily due to FX fluctuations on USD cash holdings. This contradicts the 'strong financial position' narrative, proving the balance sheet is highly vulnerable to currency volatility.
Legacy TCE Pipeline Shifted to IITs
The company's legacy Next-Gen Immune Cell Engagers (MP0317 and MP0533) are increasingly being relegated to Investigator-Initiated Trials (IITs). MP0317 is now in a Phase 2 IIT in France, and MP0533 combo trials are 'under discussion' with consortia. While this saves the company cash, it signals a clear deprioritization of these assets and drastically limits MOLN's control over trial timelines and data quality.
Other KPIs
Decelerating. Dropped sharply by CHF 56.3M from CHF 149.4M at the end of 2024. While the company claims this funds operations until 2028, this relies on a flawless execution of the newly lowered CHF 45-55M annual OpEx guidance, leaving very little room for unexpected clinical or manufacturing cost overruns.
Improving. The operating loss narrowed from CHF -61.2M in FY24, completely absorbing a CHF 2.6M restructuring charge taken in June 2025. This proves management is actually delivering on its promise to right-size the organization for a focused radiopharma clinical push.
Guidance
Decelerating aggressively from the CHF 58.1M spent in FY25. Roughly CHF 6M of this guided amount is non-cash (share-based payments, depreciation), meaning the true cash burn from operations is targeted to drop into the low CHF 40M range. Hitting this target is existential for maintaining the 2028 cash runway.
Stable compared to the previous quarter's update. This guidance explicitly excludes any potential payments from R&D partnerships, making it a true 'standalone' survival timeline.
Key Questions
Actinium-225 Supply Chain
With the new Eckert & Ziegler agreement enabling 225Ac Radio-DARPins, how is the company securing long-term supply of Actinium, given the notorious global bottlenecks for this specific isotope?
FX Risk Mitigation
Financial losses tied to USD holdings drove the net loss significantly higher in 2025. What hedging strategies are being implemented in 2026 to protect the CHF 93.1M cash pile from further foreign exchange deterioration?
Legacy Asset Monetization
With MP0621 looking for a partner and MP0317/MP0533 leaning on IITs, what is the realistic timeline for monetizing these immune engager assets, and are you willing to out-license them at a discount to focus entirely on RDTs?